People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharmaceuticals, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2023 |
| Arbor Biotechnologies, Inc. | — | Biotechnology | Series D+ | $230.6M | $5.7B | 2021 |
| Lb Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $141.4M | $1.5B | 2023 |
| SentreHEART Inc | — | Biotechnology | Series B | $51.0M | $992.2M | 2016 |
| Sagent Holding Co. | — | Pharmaceuticals | Series B | $45.8M | $204.0M | 2009 |
| Nora Therapeutics, Inc. | — | Biotechnology | Series B | $38.3M | $39.7M | 2009 |
| Nexcida Therapeutics, Inc. | — | Other | Seed | $2.8M | $51.1M | 2015 |
Chen Yu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chen Yu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| John Murphy | 1 | 17 |
| Richard Ferrari | 1 | 15 |
| Casey Tansey | 1 | 14 |
| Paul Meister | 1 | 12 |
| Keith Crandell | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Paul Buckman | 1 | 10 |
| Russell Hirsch | 1 | 10 |
| Steven Hochberg | 1 | 9 |
| Robert Ruffolo | 1 | 8 |
| Simeon George | 1 | 8 |
| Judith Li | 1 | 8 |
| Erez Chimovits | 1 | 7 |
| David Schnell | 1 | 7 |
| Brent Ahrens | 1 | 7 |
| Victor Tong | 1 | 6 |
| David Walt | 1 | 6 |
| David R. Walt | 1 | 5 |
| Donald J. Hayden, Jr. | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.